SNN Stock - Smith & Nephew plc
Unlock GoAI Insights for SNN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.81B | $5.55B | $5.21B | $5.21B | $4.56B |
| Gross Profit | $4.05B | $3.82B | $3.67B | $3.67B | $3.16B |
| Gross Margin | 69.6% | 68.8% | 70.5% | 70.4% | 69.4% |
| Operating Income | $657.00M | $425.00M | $315.00M | $593.00M | $295.00M |
| Net Income | $412.00M | $263.00M | $223.00M | $524.00M | $448.00M |
| Net Margin | 7.1% | 4.7% | 4.3% | 10.1% | 9.8% |
| EPS | $0.94 | $1.20 | $0.50 | $1.20 | $1.02 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | - |
| October 14th 2025 | Bernstein | Downgrade | Market Perform | $37.5 |
| April 25th 2025 | HSBC Securities | Downgrade | Hold | - |
| March 12th 2025 | UBS | Downgrade | Neutral | - |
| November 6th 2024 | Berenberg | Downgrade | Hold | - |
| November 1st 2024 | Deutsche Bank | Downgrade | Hold | - |
| July 24th 2024 | Deutsche Bank | Initiation | Buy | - |
| June 5th 2024 | UBS | Upgrade | Buy | - |
| November 28th 2023 | Barclays | Upgrade | Equal Weight | - |
| November 3rd 2023 | JP Morgan | Upgrade | Overweight | - |
| October 31st 2023 | HSBC Securities | Upgrade | Buy | - |
| October 13th 2023 | Stifel | Initiation | Hold | - |
| August 8th 2023 | UBS | Upgrade | Neutral | - |
| April 27th 2023 | HSBC Securities | Downgrade | Hold | - |
| April 11th 2023 | Morgan Stanley | Upgrade | Overweight | - |
Earnings History & Surprises
SNNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | — | — | — | — |
Q3 2025 | Aug 5, 2025 | $0.86 | $0.67 | -21.7% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $0.92 | $0.23 | -75.5% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $0.79 | $0.24 | -68.8% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $0.97 | $0.05 | -94.6% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $0.73 | $0.10 | -86.5% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.73 | $0.03 | -96.4% | ✗ MISS |
Q3 2022 | Jul 2, 2022 | $0.76 | $0.10 | -86.7% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.87 | $0.18 | -79.1% | ✗ MISS |
Q3 2021 | Jul 3, 2021 | $0.79 | $0.12 | -85.2% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $0.92 | $0.20 | -78.4% | ✗ MISS |
Q2 2020 | Jun 27, 2020 | $0.29 | $0.06 | -80.4% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $1.14 | $0.17 | -85.4% | ✗ MISS |
Q2 2019 | Jun 29, 2019 | — | $0.18 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.22 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.16 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.25 | — | — |
Q3 2017 | Jul 1, 2017 | — | $0.18 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.30 | — | — |
Q3 2016 | Jul 2, 2016 | — | $0.13 | — | — |
Latest News
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $34
📉 NegativeSmith+Nephew Study Finds PICO sNPWT (-80 mmHg) Outperforms Prevena (-125 mmHg) In Reducing Wound Complications, Hospital Stay, And Costs In Orthopedic And Cardiovascular Surgeries
📈 PositiveBernstein Downgrades Smith & Nephew to Market Perform, Announces $37.5 Price Target
📉 NegativeSmith+Nephew Unveils New Data From Professor Amit Gefen And His Research Group Published In 'The International Wound Journal', Demonstrating The Pressure Injury Prevention Mechanism Of Action Of ALLEVYN COMPLETE CARE Foam Dressing And Its Ability To Absorb And Dissipate Friction And Shear Forces
📈 PositiveSmith+Nephew Announces New Evidence And Market Updates Highlighting Clinical Performance Of REGENETEN Bioinductive Implant And Support Further Adoption
📈 PositiveCanaccord Genuity Maintains Hold on Smith & Nephew, Raises Price Target to $36
➖ NeutralFrequently Asked Questions about SNN
What is SNN's current stock price?
What is the analyst price target for SNN?
What sector is Smith & Nephew plc in?
What is SNN's market cap?
Does SNN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SNN for comparison